Keyphrases
Early Onset
100%
Risk Factors
100%
Stem Cell Transplantation
100%
Older Adults
100%
Venous Disease
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
30%
Post-transplantation Cyclophosphamide (PTCy)
30%
Graft-versus-host Disease Prophylaxis
20%
Chemotherapy
10%
No Significant Difference
10%
Alanine Aminotransferase
10%
Adult Patients
10%
Strong Predictor
10%
Bilirubin
10%
Transplant Experiment
10%
Life-threatening Complications
10%
Gemtuzumab Ozogamicin
10%
Aspartate Transferase
10%
Classification and Regression Tree
10%
Regression Tree Analysis
10%
Classification Tree Analysis
10%
Multivariate Classification
10%
Multivariate Regression
10%
Single-center Analysis
10%
Disease Risk Prediction
10%
Hepatic Factor
10%
Immunology and Microbiology
Cyclophosphamide
100%
Stem Cell Transplantation
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Graft-Versus-Host Disease
66%
Alanine
33%
Awareness
33%
Gemtuzumab
33%
Neuroscience
Stem Cell
100%
Cyclophosphamide
100%
Hematopoietic Cell
100%
Aspartic Acid
33%
Alanine Aminotransferase
33%
Transferase
33%
Bilirubin
33%
Gemtuzumab
33%
Medicine and Dentistry
Stem Cell Therapy
100%
Vein Occlusion
100%
Cyclophosphamide
30%
Allogeneic Hematopoietic Stem Cell Transplantation
30%
Graft Versus Host Reaction
20%
Prophylaxis
20%
Diseases
10%
Awareness
10%
Transplantation
10%
Aspartic Acid
10%
Alanine Aminotransferase
10%
Bilirubin
10%
Transferase
10%
Gemtuzumab
10%
Pharmacology, Toxicology and Pharmaceutical Science
Vein Occlusion
100%
Cyclophosphamide
30%
Graft Versus Host Reaction
20%
Diseases
10%
Chemotherapy
10%
Aspartic Acid
10%
Bilirubin
10%
Alanine Aminotransferase
10%
Transferase
10%
Gemtuzumab
10%
Nursing and Health Professions